Elizabeth Smyth, Clinical Lead at the Oxford Clinical Trials Office, shared a post on X:
“Very pleased to share this review on FGFR2b which is a key emerging biomarker in gastric and gastroesophageal cancer.
Looking forward to seeing those FORTITUDE 101 results soon!
Hopefully ESMO25 in Berlin!
Thanks to all my co-authors! ”
Title: FGFR2b protein overexpression: An emerging biomarker in vgastric and gastroesophageal junction adenocarcinoma
Journal: Cancer Treatment Reviews
Authors: Elizabeth C. Smyth, Kyoung-Mee Kim, Sun Young Rha, Zev A. Wainberg, Hayden Honeycutt, Erica Sommermann, Atsushi Ochiai
More posts featuring Elizabeth Smyth on OncoDaily.